Literature DB >> 6753851

Immune complexes in progressive systemic sclerosis (scleroderma).

J R Seibold, T A Medsger, A Winkelstein, R H Kelly, G P Rodnan.   

Abstract

Serum immune complexes were measured in 92 patients with progressive systemic sclerosis, and elevated levels were found as follows: Raji cell assay 72% (59% after pronase treatment of Raji cell), agarose gel electrophoresis 52%, and C1q binding 24%. Forty-three (47%) had abnormal results on two or more of these tests, but only 17 (18%) had normal results by all three assays. Computer-assisted analysis of immune complex results and extensive clinical and laboratory data compiled on these patients revealed that the patients with abnormal Raji cell assays more often had diffuse scleroderma, tendon friction rubs, and positive serum antinuclear antibody tests than did patients with negative results on Raji cell assays. Individuals with immune complexes detected by C1q binding had evidence of pulmonary involvement and positive serum rheumatoid factor more frequently than did patients whose C1q tests were negative.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6753851     DOI: 10.1002/art.1780251004

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  10 in total

1.  European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes.

Authors:  G Valentini; A Della Rossa; S Bombardieri; W Bencivelli; A J Silman; S D'Angelo; M M Cerinic; J F Belch; C M Black; P Bruhlmann; L Czirják; A De Luca; A A Drosos; C Ferri; A Gabrielli; R Giacomelli; G Hayem; M Inanc; N J McHugh; H Nielsen; M Rosada; R Scorza; J Stork; A Sysa; F H van den Hoogen; P J Vlachoyiannopoulos
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

2.  Serum levels of soluble CD21 in patients with systemic sclerosis.

Authors:  Manabu Tomita; Takafumi Kadono; Norihito Yazawa; Tomohiko Kawashima; Zenshiro Tamaki; Ryuichi Ashida; Hanako Ohmatsu; Yoshihide Asano; Makoto Sugaya; Masahide Kubo; Hironobu Ihn; Kunihiko Tamaki; Shinichi Sato
Journal:  Rheumatol Int       Date:  2010-10-30       Impact factor: 2.631

Review 3.  Pathogenesis of scleroderma: the interrelationship of the immune and vascular hypotheses.

Authors:  E M Sternberg
Journal:  Surv Immunol Res       Date:  1985

4.  The complement system and systemic sclerosis.

Authors:  C Benbassat; M Schlesinger; C Luderschmidt; G Valentini; G Tirri; Y Shoenfeld
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

5.  Systemic sclerosis: a collagen or microvascular disease?

Authors:  M I Jayson
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-23

6.  Decreased nailfold capillary density in Raynaud's phenomenon: a reflection of immunologically mediated local and systemic vascular disease?

Authors:  P M Houtman; C G Kallenberg; A A Wouda; T H The
Journal:  Ann Rheum Dis       Date:  1985-09       Impact factor: 19.103

7.  Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis.

Authors:  Xia Gao; Guiquan Jia; Anna Guttman; Daryle J DePianto; Katrina B Morshead; Kai-Hui Sun; Nandhini Ramamoorthi; Jason A Vander Heiden; Zora Modrusan; Paul J Wolters; Angelika Jahreis; Joseph R Arron; Dinesh Khanna; Thirumalai R Ramalingam
Journal:  Cell Rep Med       Date:  2020-11-17

Review 8.  Gene expression profiling offers insights into the role of innate immune signaling in SSc.

Authors:  Michael E Johnson; Patricia A Pioli; Michael L Whitfield
Journal:  Semin Immunopathol       Date:  2015-07-30       Impact factor: 9.623

Review 9.  Systemic sclerosis--a microvascular disorder?

Authors:  M I Jayson
Journal:  J R Soc Med       Date:  1983-08       Impact factor: 18.000

10.  Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts.

Authors:  Elena Raschi; Cecilia Beatrice Chighizola; Laura Cesana; Daniela Privitera; Francesca Ingegnoli; Claudio Mastaglio; Pier Luigi Meroni; Maria Orietta Borghi
Journal:  Arthritis Res Ther       Date:  2018-08-29       Impact factor: 5.156

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.